Breo Ellipta / Fluticasone furoate and vilanterol trifenatate
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Trelegy Ellipta / Fluticasone furoate, umeclidinium bromide and vilanterol trifenatate
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lescol / Fluvastatin sodium
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Lescol XL / Fluvastatin sodium
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Foscavir / Foscarnet sodium
Dose or interval change · Body-weight-normalized CrCl, mL/min/kg
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Rukobia / Fostemsavir tromethamine
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Faslodex / Fulvestrant
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Furoscix / Furosemide
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Emgality / Galcanezumab-gnlm
Evidence gap · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Columvi / Glofitamab-gxbm
Evidence gap · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Sancuso / Granisetron
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
DILAUDID injection / DILAUDID-HP / Dilaudid / Hydromorphone hydrochloride
Dose or interval change · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Hydrea / Hydroxyurea
Dose or interval change · Measured creatinine clearance, mL/min
Local official-label summary. Read the exact source scope and cautions.
SIKLOS / Hydroxyurea
Dose or interval change · Measured creatinine clearance, mL/min
Local official-label summary. Read the exact source scope and cautions.
Vascepa / Icosapent ethyl
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Primaxin I.V. / Imipenem and cilastatin sodium
Dose or interval change · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Besponsa / Inotuzumab ozogamicin
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Fiasp / Insulin aspart
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
NovoLog / Insulin aspart
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Levemir / Insulin detemir
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lantus / Insulin glargine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Toujeo / Insulin glargine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Humalog / Insulin lispro
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lyumjev / Insulin lispro-aabc
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Avalide / Irbesartan and hydrochlorothiazide
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Corlanor / Ivabradine
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tibsovo / Ivosidenib
No adjustment within stated limits · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
Sprix / Ketorolac tromethamine
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Epivir / Lamivudine
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lamictal XR / Lamotrigine
Dose or interval change · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lamictal / Lamotrigine
Dose or interval change · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Dayvigo / Lemborexant
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Revlimid / Lenalidomide
Dose or interval change · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
Keppra / Levetiracetam / Roweepra
Dose or interval change · CrCl normalized to 1.73 m2, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
Spritam / Levetiracetam
Dose or interval change · CrCl normalized to 1.73 m2, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tradjenta / Linagliptin
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Generic names and brands can lead to different formulations. Select the matching route and release type.
Renal tables retain their indication, units and dialysis assumptions. Do not combine doses and intervals from different protocols.
Read source qualifications, monitoring and interactions. A missing dose or absent result does not mean no adjustment.
See all 26 A-Z review statuses and remaining work | Current evidence additions and verification results
1215 product/formulation records and 1125 selected RX summaries are local. These are selected renal summaries, not complete prescribing monographs. Coverage and independent clinical review remain incomplete.
Review coverage details